Swiss pharma giant Novartis (NOVN: VX) has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx (secukinumab), as well as the Prix Galien Foundation "Discovery of the Decade" award for Best Pharmaceutical Product for the drug Gleevec (imatinib mesylate). The awards were presented at a ceremony in New York City.
"We are honored to receive these prestigious awards for Cosentyx and Gleevec, which not only have changed the practice of medicine for certain conditions, but also represent years of hard work by our scientists," said Joseph Jimenez, chief executive of Novartis, adding "These wins underscore our commitment to addressing the unmet medical needs of patients through science-based innovation."
Cosentyx was the first fully human interleukin-17A (IL-17A) antagonist approved by the US Food and Drug Administration in 2015 for the treatment of adults with moderate to severe plaque psoriasis. Cosentyx was also approved for the treatment of active ankylosing spondylitis and psoriatic arthritis in 2016.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze